Home・Akciju saraksts・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Atvērts

3.51 -2.77

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.45

Max

3.65

Galvenie mērījumi
By Trading Economics
Ienākumi	-42M -78M
EPS	-0.59
Darbinieki	106
EBITDA	-42M -77M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+146.05% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 6. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	47M 378M
Iepriekšējā atvēršanas cena	6.28
Iepriekšējā slēgšanas cena	3.51

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 10. sept. 23:56 UTC

Correlated Moves

NiSource Inc shares are lower in after-market trading, continuing a decline from Thursday's close, alongside CMS Energy Corp's decrease amid broader market pressures.

2026. g. 10. sept. 23:56 UTC

Macro News

Copper prices are lower as rising crude oil prices above $100 create negative market sentiment. Increased treasury yields also contribute to cautious outlooks for commodities.

2026. g. 10. sept. 23:56 UTC

Plexus Corp shares rose in after-hours trading, rebounding sharply from an early decline. No specific news was identified to explain the movement.

2026. g. 10. sept. 23:56 UTC

State Street Corp shares are trading lower in after-market hours. No specific news was identified to explain this movement.

2026. g. 10. sept. 23:56 UTC

PPL Corp shares are trading slightly higher in after-market hours, reflecting a modest advance since Thursday's close amid recent trading pressure.

2026. g. 10. sept. 23:56 UTC

Dollar Tree Inc. shares are higher in after-market trading, gaining slightly since Thursday's close, though remaining below the 20-day moving average.

2026. g. 10. sept. 23:56 UTC

Flowers Foods Inc shares are higher in after-market trading, rebounding from an early dip. The stock remains below its 20-day moving average.

2026. g. 10. sept. 23:56 UTC

UFP Technologies Inc shares are higher in after-market trading, showing notable upward movement since Thursday's close, despite recent declines and no specific news.

2026. g. 10. sept. 23:56 UTC

Medtronic PLC shares are lower in after-market hours, continuing a trend from recent sessions. Volatility marked today's trading, with no specific news identified.

2026. g. 10. sept. 23:52 UTC

The AUD/CHF is trading lower today, with no specific news identified. It remains near the upper end of its one-month trading range.

2026. g. 10. sept. 23:51 UTC

News

The Nikkei 225 Index is lower in after-market hours, pressured by rising oil prices above $100 and a recent European Central Bank rate hike.

2026. g. 10. sept. 23:51 UTC

Shares of Frontier Group Holdings Inc. are lower in after-market hours, continuing a decline over the past four sessions amid broader market trends.

2026. g. 10. sept. 23:51 UTC

CVS Health shares are higher in after-market trading, rebounding from earlier losses amid mixed economic data and broader market trends.

2026. g. 10. sept. 23:51 UTC

Texas Pacific Land Corp shares are lower in after-market hours, continuing a trend of three consecutive sessions finishing down and trading below the 20-day moving average.

2026. g. 10. sept. 23:51 UTC

iQIYI Inc shares are higher in after-market trading, recovering from an earlier decline. The stock remains below its 20-day moving average.

2026. g. 10. sept. 23:51 UTC

UiPath Inc. shares are lower in after-market trading, remaining below the 20-day moving average and near the lower end of their one-month range.

2026. g. 10. sept. 23:51 UTC

Progressive Corp shares are lower in after-market hours. No specific news was identified to explain the decline.

2026. g. 10. sept. 23:51 UTC

Regal Rexnord Corp shares rose in after-market trading, recovering from an initial dip. The price remains below its 20-day moving average.

2026. g. 10. sept. 23:51 UTC

Michigan Consumer Sentiment Preliminary Report for September 2026 Forecasts Continued Low Confidence at 51.0 Amid Rising Inflation Concerns

2026. g. 10. sept. 23:51 UTC

Canada's Housing Starts Data Release on September 16, 2026, Sparks Concerns Over Slowing Construction and Affordability Challenges.

2026. g. 10. sept. 23:51 UTC

Macro News

The Euro Stoxx 50 Index is lower in after-market hours, pressured by rising crude oil prices above $100 and concerns over inflation and interest rates.

2026. g. 10. sept. 23:51 UTC

Consolidated Edison shares moved higher in after-hours trading, recovering from a session low. The stock is positioned near the midpoint of its one-month trading range.

2026. g. 10. sept. 23:51 UTC

Zeta Global Holdings Corp. shares are lower in after-market hours, continuing a downward trend observed since Thursday's close amid broader market conditions.

2026. g. 10. sept. 23:51 UTC

Correlated Moves

WEC Energy Group shares are higher in after-market hours, influenced by a rise in Consolidated Edison and broader utility sector trends.

2026. g. 10. sept. 23:51 UTC

APTIV PLC shares are lower in after-market hours, continuing a downward trend since Thursday's close. The stock remains below its 20-day moving average.

2026. g. 10. sept. 23:51 UTC

The AUD/JPY is trading lower, continuing a downward trend since Wednesday. It remains near the lower end of its one-month trading range.

2026. g. 10. sept. 23:51 UTC

The AUD/NZD is trading lower today, with no specific news identified for the decline. It remains below Wednesday's close after earlier fluctuations.

2026. g. 10. sept. 23:46 UTC

Correlated Moves

Parker-Hannifin Corp shares are lower in after-market hours, continuing recent declines influenced by Timken Co's drop and broader industrial sector sentiment.

2026. g. 10. sept. 23:46 UTC

Correlated Moves

News

Valero Energy Corp is trading higher in after-market hours following a Power Inflow alert, reflecting increased buying interest among investors.

2026. g. 10. sept. 23:46 UTC

Leidos Holdings Inc shares are higher in after-market trading. No specific company news was identified to explain this price movement.

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

146.05% augšup

Prognoze 12 mēnešiem

Vidējais 8.833 USD 146.05%

Augstākais 11 USD

Zemākais 5 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.